Domestic MedTech gets shot in the arm with First Fund launched

AMTZ partners with MedArtha Capital to accelerate Innovation, Research and Manufacturing in Medical Devices Domain

Mumbai: India’s medical technology sector received a major boost with the launch of a dedicated MedTech Capital fund, aimed at accelerating innovation, research, and manufacturing in the country’s growing medical device ecosystem.

The platform, created through a partnership between Andhra Pradesh MedTech Zone (AMTZ) and MedArtha Capital, India’s MedTech Capital Fund, was unveiled in Mumbai by Union Minister for Commerce and Industry Hon’ble Shri Piyush Goyal. The initiative provides growth capital and strategic support to emerging medical device companies, strengthens domestic manufacturing, and aims to create multiple globally competitive MedTech leaders.

Speaking at the launch, Shri Piyush Goyal described India’s MedTech sector as a “sunrise opportunity,” citing the country’s expanding talent pool and rising preventive healthcare awareness.

“India’s growing talent pool and rising preventive health awareness make MedTech a true sunrise opportunity. Platforms like this help bridge innovation and capital, enabling startups to scale, advance research, and strengthen manufacturing capabilities across the medical technology value chain,” Mr Goyal added.

Ganesh Sabat, Managing Partner of MedArtha Capital, said: “Scaling large, global medical technology companies requires the right capital, deep domain expertise, and access to specialized manufacturing infrastructure like AMTZ. MedArtha Capital is an operator-led investment platform that works closely with entrepreneurs to build globally competitive medical device companies from India.”

Dr Jitendra Sharma, MD & Founder CEO of AMTZ, added: “At AMTZ we have seen first-hand the innovation emerging from Indian MedTech entrepreneurs. Platforms like MedArtha Capital can play a pivotal role in building the next generation of global medical technology companies from India. With strong engineering, clinical expertise, and cost-efficient manufacturing, India has the potential to produce globally significant medical device companies.”

The launch also featured a high-level panel discussion emphasizing the importance of collaboration between investors, innovators, manufacturers, and policymakers in building a self-reliant, globally competitive MedTech ecosystem. The session was moderated by Mr Niraj Shah, Executive Editor at NDTV, and Ganesh Sabat, Managing Partner, MedArtha Capital, with distinguished panellists including Ms Swati Bansal, from the National Investment and Infrastructure Fund, Mr Bhargav Kotadia MD and CEO of SMT, and Mr Abhishek Kabra, Managing Director at Samara Capital.

As global demand for medical technologies grows, India is well-positioned to become a hub for high-quality, cost-effective medical devices, combining capital, infrastructure, and expertise to reduce imports and create globally competitive MedTech companies.

Related Posts

A SSi Mantra fame Robotic Telesurgery Champion pulls off another Spectacular Intercontinental

Over 10, 000 Km afar Australia & India shrank into an OT New Delhi: The chemistry between best in class ‘made in India’ surgical robotic system SSi Mantra and unique…

To Eat or not to Eat, if this Dilemma is ‘Eating’ you, ‘Eat’ this Book

New ‘Bible’ of Nearly ‘Ideal’ Eating hit stands to become Instant Best Seller New Delhi: You are a veritable Hamlet when it comes to the question, to eat or not…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Six Women Develop Serious Complications After C-Section

Six Women Develop Serious Complications After C-Section

Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

Indian Pharma Majors Plan to Invest in US

Indian Pharma Majors Plan to Invest in US

Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr

Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr

Fake Cancer Drug Racket: Delhi HC Grants Bail, Flags Gaps in ED Probe

Fake Cancer Drug Racket: Delhi HC Grants Bail, Flags Gaps in ED Probe

A SSi Mantra fame Robotic Telesurgery Champion pulls off another Spectacular Intercontinental

A SSi Mantra fame Robotic Telesurgery Champion pulls off another Spectacular Intercontinental